Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E. Radford Decker

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|May 17, 2003
Nonpeptide endothelin antagonists in clinical developmentChengde Wu, E. Radford Decker, George W. Holland, et al.
Journal of Medicinal Chemistry|April 2, 2004
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonistChengde Wu, E Radford Decker, Natalie Blok, et al.
Biochemical and Biophysical Research Communications|September 3, 2010
Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1Peter Vanderslice, Darren G Woodside, Amy R Caivano, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Drugs of Today (Barcelona, Spain : 1998)|May 17, 2003
Nonpeptide endothelin antagonists in clinical developmentChengde Wu, E. Radford Decker, George W. Holland, et al.
Journal of Medicinal Chemistry|April 2, 2004
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonistChengde Wu, E Radford Decker, Natalie Blok, et al.
Biochemical and Biophysical Research Communications|September 3, 2010
Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1Peter Vanderslice, Darren G Woodside, Amy R Caivano, et al.
Pageof 1